{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:14:23Z","timestamp":1792066463558,"version":"4.4.0"},"reference-count":194,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007458","name":"Qatar Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007458","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As global life expectancy increases, the prevalence of neurodegenerative diseases like Alzheimer\u2019s disease (AD) continues to rise. Since therapeutic options are minimal, a deeper understanding of the pathophysiology is essential for improved diagnosis and treatments. AD is marked by the aggregation of A\u03b2 proteins, tau hyperphosphorylation, and progressive neuronal loss, though its precise origins remain poorly understood. Meanwhile, type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, leading to the formation of advanced glycation end products (AGEs), which are implicated in tissue damage and neurotoxicity. These AGEs can be resistant to proteolysis and, therefore, accumulate, exacerbating AD pathology and accelerating neurodegeneration. Insulin resistance, a hallmark of T2DM, further complicates AD pathogenesis by promoting tau hyperphosphorylation and A\u03b2 plaque accumulation. Additionally, gut microbiome dysbiosis in T2DM fosters AGE accumulation and neuroinflammation, underscoring the intricate relationship between metabolic disorders, gut health, and neurodegenerative processes. This complex interplay presents both a challenge and a potential avenue for therapeutic intervention. Emerging evidence suggests that antidiabetic medications may offer cognitive benefits in AD, as well as in other neurodegenerative conditions, pointing to a shared pathophysiology. Thus, we posit that targeting AGEs, insulin signaling, and gut microbiota dynamics presents promising opportunities for innovative treatment approaches in AD and T2DM.<\/jats:p>","DOI":"10.1007\/s12035-025-05051-9","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T10:34:20Z","timestamp":1747910060000},"page":"14859-14882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Glycation in Alzheimer\u2019s Disease and Type 2 Diabetes: The Prospect of Dual Drug Approaches for Therapeutic Interventions"],"prefix":"10.1007","volume":"62","author":[{"given":"Sama","family":"Ayoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Al-Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Laswi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago F.","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Chaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"6","key":"5051_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963","journal-title":"Nat Med"},{"key":"5051_CR2","doi-asserted-by":"publisher","first-page":"937486","DOI":"10.3389\/fnagi.2022.937486","volume":"14","author":"X Li","year":"2022","unstructured":"Li X, Feng X, Sun X, Hou N, Han F, Liu Y (2022) Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132019. Front Aging Neurosci 14:937486","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"5051_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-017-1709-7","volume":"134","author":"TL Spires-Jones","year":"2017","unstructured":"Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol (Berl) 134(2):187\u2013205","journal-title":"Acta Neuropathol (Berl)"},{"issue":"3","key":"5051_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23(3):1851","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5051_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ (2020) Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 10(1):107\u2013111","journal-title":"J Epidemiol Glob Health"},{"issue":"17","key":"5051_CR6","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB et al (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21(17):6275","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5051_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4239\/wjd.v12.i6.745","volume":"12","author":"M Rojas","year":"2021","unstructured":"Rojas M, Ch\u00e1vez-Castillo M, Bautista J, Ortega \u00c1, Nava M, Salazar J et al (2021) Alzheimer\u2019s disease and type 2 diabetes mellitus: pathophysiologic and pharmacotherapeutics links. World J Diabetes 12(6):745\u2013766","journal-title":"World J Diabetes"},{"issue":"4","key":"5051_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/biom12040542","volume":"12","author":"M Khalid","year":"2022","unstructured":"Khalid M, Petroianu G, Adem A (2022) Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules 12(4):542","journal-title":"Biomolecules"},{"issue":"3","key":"5051_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","volume":"126","author":"L Gu","year":"2013","unstructured":"Gu L, Guo Z (2013) Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils. J Neurochem 126(3):305\u2013311","journal-title":"J Neurochem"},{"key":"5051_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7361613","volume":"2016","author":"SK Singh","year":"2016","unstructured":"Singh SK, Srivastav S, Yadav AK, Srikrishna S, Perry G (2016) Overview of Alzheimer\u2019s disease and some therapeutic approaches targeting A \u03b2 by using several synthetic and herbal compounds. Oxid Med Cell Longev 2016:1\u201322","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"5051_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000007969","volume":"40","author":"JP Brion","year":"1998","unstructured":"Brion JP (1998) Neurofibrillary tangles and Alzheimer\u2019s disease. Eur Neurol 40(3):130\u2013140","journal-title":"Eur Neurol"},{"issue":"24","key":"5051_CR12","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25(24):5789","journal-title":"Molecules"},{"issue":"5","key":"5051_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11055-017-0427-x","volume":"47","author":"VN Mukhin","year":"2017","unstructured":"Mukhin VN, Pavlov KI, Klimenko VM (2017) Mechanisms of neuron loss in Alzheimer\u2019s disease. Neurosci Behav Physiol 47(5):508\u2013516","journal-title":"Neurosci Behav Physiol"},{"issue":"1","key":"5051_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/1673-5374.375317","volume":"19","author":"G Hussain","year":"2024","unstructured":"Hussain G, Akram R, Anwar H, Sajid F, Iman T, Han HS et al (2024) Adult neurogenesis. Neural Regen Res 19(1):6\u201315","journal-title":"Neural Regen Res"},{"issue":"8","key":"5051_CR15","doi-asserted-by":"publisher","first-page":"e24293","DOI":"10.1371\/journal.pone.0024293","volume":"6","author":"S Chen","year":"2011","unstructured":"Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD (2011) Allopregnanolone promotes regeneration and reduces \u03b2-amyloid burden in a preclinical model of Alzheimer\u2019s disease. PLoS ONE 6(8):e24293","journal-title":"PLoS ONE"},{"issue":"4","key":"5051_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/156720506778249470","volume":"3","author":"X Zhu","year":"2006","unstructured":"Zhu X, Raina A, Perry G, Smith M (2006) Apoptosis in Alzheimer disease: a mathematical improbability. Curr Alzheimer Res 3(4):393\u2013396","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"5051_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH (2023) Neuroinflammation in Alzheimer\u2019s disease: current progress in molecular signaling and therapeutics. Inflammation 46(1):1\u201317","journal-title":"Inflammation"},{"key":"5051_CR18","first-page":"11","volume":"30","author":"AL Hemonnot","year":"2019","unstructured":"Hemonnot AL, Hua J, Ulmann L, Hirbec H (2019) Microglia in Alzheimer disease: well-known targets and new opportunities. Front Aging Neurosci 30:11","journal-title":"Front Aging Neurosci"},{"key":"5051_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.14283\/jpad.2020.18","volume":"7","author":"S Gauthier","year":"2020","unstructured":"Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R et al (2020) NON-amyloid approaches to disease modification for Alzheimer\u2019s Disease: an EU\/US CTAD task force report. J Prev Alzheimers Dis. 7:152\u2013157","journal-title":"J Prev Alzheimers Dis."},{"issue":"10","key":"5051_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrneurol.2010.130","volume":"6","author":"C Sims-Robinson","year":"2010","unstructured":"Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6(10):551\u2013559","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"5051_CR21","first-page":"421","volume":"8","author":"J Derk","year":"2018","unstructured":"Derk J, MacLean M, Juranek J, Schmidt AM (2018) The receptor for advanced glycation endproducts (RAGE) and mediation of inflammatory neurodegeneration. J Alzheimers Dis Park 8(1):421","journal-title":"J Alzheimers Dis Park"},{"issue":"12","key":"5051_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fnagi.2020.00217","volume":"22","author":"Y Kong","year":"2020","unstructured":"Kong Y, Wang F, Wang J, Liu C, Zhou Y, Xu Z et al (2020) Pathological mechanisms linking diabetes mellitus and Alzheimer\u2019s disease: the receptor for advanced glycation end products (RAGE). Front Aging Neurosci 22(12):217","journal-title":"Front Aging Neurosci"},{"key":"5051_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ibneur.2022.12.006","volume":"14","author":"M Gupta","year":"2023","unstructured":"Gupta M, Pandey S, Rumman M, Singh B, Mahdi AA (2023) Molecular mechanisms underlying hyperglycemia associated cognitive decline. IBRO Neurosci Rep 14:57\u201363","journal-title":"IBRO Neurosci Rep"},{"issue":"6","key":"5051_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jada.2010.03.018","volume":"110","author":"J Uribarri","year":"2010","unstructured":"Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110(6):911-916.e12","journal-title":"J Am Diet Assoc"},{"issue":"3","key":"5051_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/hm.hm_31_22","volume":"6","author":"SH Hooshiar","year":"2022","unstructured":"Hooshiar SH, Esmaili H, Taherian A, Jafarnejad S (2022) Exercise, advanced glycation end products, and their effects on cardiovascular disorders: a narrative review. Heart Mind 6(3):139\u2013150","journal-title":"Heart Mind"},{"issue":"5","key":"5051_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4158\/1934-2403-26.5.576","volume":"26","author":"MS Beeri","year":"2020","unstructured":"Beeri MS, Uribarri J, Cai W, Buchman AS, Haroutunian V (2020) Human brain and serum advanced glycation end products are highly correlated: preliminary results of their role in Alzheimer disease and type 2 diabetes. Endocr Pract 26(5):576\u2013577","journal-title":"Endocr Pract"},{"key":"5051_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/734956","volume":"2012","author":"L Perrone","year":"2012","unstructured":"Perrone L, Sbai O, Nawroth PP, Bierhaus A (2012) The complexity of sporadic Alzheimer\u2019s disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimers Dis 2012:1\u201313","journal-title":"Int J Alzheimers Dis"},{"issue":"10","key":"5051_CR28","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26(10):5481\u20135503","journal-title":"Mol Psychiatry"},{"issue":"9","key":"5051_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/antiox10091479","volume":"10","author":"E Tamagno","year":"2021","unstructured":"Tamagno E, Guglielmotto M, Vasciaveo V, Tabaton M (2021) Oxidative stress and beta amyloid in Alzheimer\u2019s disease. Which comes first: the chicken or the egg? Antioxid Basel Switz. 10(9):1479","journal-title":"Antioxid Basel Switz."},{"issue":"5","key":"5051_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/acschemneuro.7b00410","volume":"9","author":"K Batkulwar","year":"2018","unstructured":"Batkulwar K, Godbole R, Banarjee R, Kassaar O, Williams RJ, Kulkarni MJ (2018) Advanced glycation end products modulate amyloidogenic APP processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer\u2019s disease. ACS Chem Neurosci 9(5):988\u20131000","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"5051_CR31","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","volume":"269","author":"G Giacomucci","year":"2022","unstructured":"Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V et al (2022) Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. J Neurol 269(8):4270\u20134280","journal-title":"J Neurol"},{"issue":"5","key":"5051_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","volume":"36","author":"L Mosconi","year":"2009","unstructured":"Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y et al (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 36(5):811\u2013822","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5051_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-023-01203-y","volume":"15","author":"JA Pillai","year":"2023","unstructured":"Pillai JA, Bena J, Bekris L, Kodur N, Kasumov T, Leverenz JB et al (2023) Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer\u2019s disease. Alzheimers Res Ther 15(1):54","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"5051_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/mds.26566","volume":"31","author":"H Vicente Miranda","year":"2016","unstructured":"Vicente Miranda H, El-Agnaf OMA, Outeiro TF (2016) <scp>G<\/scp> lycation in <scp>P<\/scp> arkinson\u2019s disease and Alzheimer\u2019s disease. Mov Disord 31(6):782\u2013790","journal-title":"Mov Disord"},{"issue":"2","key":"5051_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00002512-199609020-00001","volume":"9","author":"SR Thorpe","year":"1996","unstructured":"Thorpe SR, Baynes JW (1996) Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9(2):69\u201377","journal-title":"Drugs Aging"},{"issue":"6","key":"5051_CR36","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1038\/cddis.2013.180","volume":"4","author":"XH Li","year":"2013","unstructured":"Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, Lv BL et al (2013) Glycation exacerbates the neuronal toxicity of \u03b2-amyloid. Cell Death Dis 4(6):e673\u2013e673","journal-title":"Cell Death Dis"},{"issue":"12","key":"5051_CR37","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/glycob\/cwac060","volume":"32","author":"NS Bangar","year":"2022","unstructured":"Bangar NS, Gvalani A, Ahmad S, Khan MS, Tupe RS (2022) Understanding the role of glycation in the pathology of various non-communicable diseases along with novel therapeutic strategies. Glycobiology 32(12):1068\u20131088","journal-title":"Glycobiology"},{"issue":"6","key":"5051_CR38","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1038\/cddis.2013.180","volume":"4","author":"XH Li","year":"2013","unstructured":"Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, Lv BL et al (2013) Glycation exacerbates the neuronal toxicity of \u03b2-amyloid. Cell Death Dis 4(6):e673","journal-title":"Cell Death Dis"},{"issue":"5","key":"5051_CR39","first-page":"e61373","volume":"16","author":"D Kothandan","year":"2024","unstructured":"Kothandan D, Singh DS, Yerrakula G, Backkiyashree D, Pratibha N, Santhana Sophia BV et al (2024) Advanced glycation end products-induced Alzheimer\u2019s disease and its novel therapeutic approaches: a comprehensive review. Cureus. 16(5):e61373","journal-title":"Cureus."},{"issue":"2","key":"5051_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/acel.12436","volume":"15","author":"I Lubitz","year":"2016","unstructured":"Lubitz I, Ricny J, Atrakchi-Baranes D, Shemesh C, Kravitz E, Liraz-Zaltsman S et al (2016) High dietary advanced glycation end products are associated with poorer spatial learning and accelerated A\u03b2 deposition in an Alzheimer mouse model. Aging Cell 15(2):309\u2013316","journal-title":"Aging Cell"},{"issue":"12","key":"5051_CR41","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.3390\/ijms22126609","volume":"22","author":"I Sirangelo","year":"2021","unstructured":"Sirangelo I, Iannuzzi C (2021) Understanding the role of protein glycation in the amyloid aggregation process. Int J Mol Sci 22(12):6609","journal-title":"Int J Mol Sci"},{"issue":"11","key":"5051_CR42","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1084\/jem.20171406","volume":"214","author":"A Montagne","year":"2017","unstructured":"Montagne A, Zhao Z, Zlokovic BV (2017) Alzheimer\u2019s disease: a matter of blood\u2013brain barrier dysfunction? J Exp Med 214(11):3151\u20133169","journal-title":"J Exp Med"},{"issue":"1","key":"5051_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3233\/JAD-131901","volume":"41","author":"TP Ng","year":"2014","unstructured":"Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41(1):61\u201368","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"5051_CR44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E et al (2003) RAGE mediates amyloid-\u03b2 peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907\u2013913","journal-title":"Nat Med"},{"key":"5051_CR45","doi-asserted-by":"publisher","unstructured":"Gasparotto J, Somensi N, Girardi CS, Bittencourt RR, de Oliveira LM, Hoefel LP, Scheibel IM, Peixoto DO et al (2024) Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson\u2019s disease. J Neurochem 168:1608\u20131624. https:\/\/doi.org\/10.1111\/jnc.15890","DOI":"10.1111\/jnc.15890"},{"issue":"6593","key":"5051_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al (1996) RAGE and amyloid-\u03b2 peptide neurotoxicity in Alzheimer\u2019s disease. Nature 382(6593):685\u2013691","journal-title":"Nature"},{"issue":"47","key":"5051_CR47","doi-asserted-by":"publisher","first-page":"20021","DOI":"10.1073\/pnas.0905686106","volume":"106","author":"K Takuma","year":"2009","unstructured":"Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H et al (2009) RAGE-mediated signaling contributes to intraneuronal transport of amyloid-\u03b2 and neuronal dysfunction. Proc Natl Acad Sci 106(47):20021\u201320026","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5051_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jocn.2012.06.005","volume":"20","author":"F Liang","year":"2013","unstructured":"Liang F, Jia J, Wang S, Qin W, Liu G (2013) Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer\u2019s disease. J Clin Neurosci 20(3):357\u2013361","journal-title":"J Clin Neurosci"},{"key":"5051_CR49","doi-asserted-by":"publisher","unstructured":"Wojsiat J, Zoltowska KM, Laskowska-Kaszub K, Wojda U (2018) Oxidant\/antioxidant imbalance in Alzheimer\u2019s disease: therapeutic and diagnostic prospects. Oxid Med Cell Longev 2018:6435861. https:\/\/doi.org\/10.1155\/2018\/6435861","DOI":"10.1155\/2018\/6435861"},{"issue":"19","key":"5051_CR50","doi-asserted-by":"publisher","first-page":"14450","DOI":"10.3390\/ijms241914450","volume":"24","author":"IM Veselov","year":"2023","unstructured":"Veselov IM, Vinogradova DV, Maltsev AV, Shevtsov PN, Spirkova EA, Bachurin SO et al (2023) Mitochondria and oxidative stress as a link between Alzheimer\u2019s disease and diabetes mellitus. Int J Mol Sci 24(19):14450","journal-title":"Int J Mol Sci"},{"issue":"10","key":"5051_CR51","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/s41401-019-0239-3","volume":"40","author":"X Liu","year":"2019","unstructured":"Liu X, Wang W, Chen HL, Zhang HY, Zhang NX (2019) Interplay between Alzheimer\u2019s disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP\/PS1 transgenic mice. Acta Pharmacol Sin 40(10):1259\u201368","journal-title":"Acta Pharmacol Sin"},{"key":"5051_CR52","doi-asserted-by":"publisher","unstructured":"Madhusudhanan J, Suresh G, Devanathan V (2020) Neurodegeneration in type 2 diabetes: Alzheimer\u2019s as a case study. Brain Behav. 10:e01577. https:\/\/doi.org\/10.1002\/brb3.1577","DOI":"10.1002\/brb3.1577"},{"issue":"5","key":"5051_CR53","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","volume":"32","author":"V Srikanth","year":"2011","unstructured":"Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D et al (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease. Neurobiol Aging 32(5):763\u2013777","journal-title":"Neurobiol Aging"},{"key":"5051_CR54","doi-asserted-by":"publisher","first-page":"238485","DOI":"10.1155\/2014\/238485","volume":"2014","author":"C Angeloni","year":"2014","unstructured":"Angeloni C, Zambonin L, Hrelia S (2014) Role of methylglyoxal in Alzheimer\u2019s disease. BioMed Res Int 2014:238485","journal-title":"BioMed Res Int"},{"issue":"6","key":"5051_CR55","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/hmg\/ddy017","volume":"27","author":"F Fang","year":"2018","unstructured":"Fang F, Yu Q, Arancio O, Chen D, Gore SS, Yan SS et al (2018) RAGE mediates A\u03b2 accumulation in a mouse model of Alzheimer\u2019s disease via modulation of \u03b2- and \u03b3-secretase activity. Hum Mol Genet 27(6):1002\u20131014","journal-title":"Hum Mol Genet"},{"issue":"10","key":"5051_CR56","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4103\/1673-5374.193234","volume":"11","author":"A Metaxas","year":"2016","unstructured":"Metaxas A, Kempf S (2016) Neurofibrillary tangles in Alzheimer\u2019s disease: elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen Res 11(10):1579","journal-title":"Neural Regen Res"},{"issue":"6","key":"5051_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41419-023-05909-7","volume":"14","author":"M Qu","year":"2023","unstructured":"Qu M, Zuo L, Zhang M, Cheng P, Guo Z, Yang J et al (2023) High glucose induces tau hyperphosphorylation in hippocampal neurons via inhibition of ALKBH5-mediated Dgkh m6A demethylation: a potential mechanism for diabetic cognitive dysfunction. Cell Death Dis 14(6):385","journal-title":"Cell Death Dis"},{"issue":"21","key":"5051_CR58","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Reddy PH (2022) Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies. Int J Mol Sci 23(21):12841","journal-title":"Int J Mol Sci"},{"key":"5051_CR59","first-page":"13","volume":"18","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S, Ryh\u00e4nen S, Marttinen M, Wittrahm R, Takalo M, Kemppainen S et al (2019) Altered insulin signaling in Alzheimer\u2019s disease brain \u2013 special emphasis on PI3K-Akt pathway. Front Neurosci 18:13","journal-title":"Front Neurosci"},{"key":"5051_CR60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2022.12.016","volume":"539","author":"AM Amin","year":"2023","unstructured":"Amin AM, Mostafa H, Khojah HMJ (2023) Insulin resistance in Alzheimer\u2019s disease: the genetics and metabolomics links. Clin Chim Acta 539:215\u2013236","journal-title":"Clin Chim Acta"},{"issue":"12","key":"5051_CR61","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1111\/ene.15039","volume":"28","author":"C Motta","year":"2021","unstructured":"Motta C, Assogna M, Bonomi CG, Mascolo AP, De Lucia V, Semprini R et al (2021) Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer\u2019s disease patients with the APOE4 genotype. Eur J Neurol 28(12):3965\u20133971","journal-title":"Eur J Neurol"},{"key":"5051_CR62","first-page":"10","volume":"11","author":"Y Lu","year":"2018","unstructured":"Lu Y, Jiang X, Liu S, Li M (2018) Changes in cerebrospinal fluid tau and \u03b2-amyloid levels in diabetic and prediabetic patients: a meta-analysis. Front Aging Neurosci 11:10","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"5051_CR63","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3390\/ijms24043506","volume":"24","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Hwang J, Son SU, Choi J, You SW, Park H et al (2023) How can insulin resistance cause Alzheimer\u2019s disease? Int J Mol Sci 24(4):3506","journal-title":"Int J Mol Sci"},{"issue":"10","key":"5051_CR64","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.3390\/ijms23105574","volume":"23","author":"FA Cimini","year":"2022","unstructured":"Cimini FA, Perluigi M, Barchetta I, Cavallo MG, Barone E (2022) Role of biliverdin reductase A in the regulation of insulin signaling in metabolic and neurodegenerative diseases: an update. Int J Mol Sci 23(10):5574","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5051_CR65","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41366-024-01490-x","volume":"48","author":"M Cai","year":"2024","unstructured":"Cai M, Wan J, Cai K, Li S, Du X, Song H et al (2024) The mitochondrial quality control system: a new target for exercise therapeutic intervention in the treatment of brain insulin resistance-induced neurodegeneration in obesity. Int J Obes 48(6):749\u2013763","journal-title":"Int J Obes"},{"issue":"15","key":"5051_CR66","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/jnr.21787","volume":"86","author":"CG Jolivalt","year":"2008","unstructured":"Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA et al (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer\u2019s disease and correction by insulin. J Neurosci Res 86(15):3265\u20133274","journal-title":"J Neurosci Res"},{"issue":"2","key":"5051_CR67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/JAD-2002-4203","volume":"4","author":"M Meli","year":"2002","unstructured":"Meli M, Perier C, Ferron C, Parssegny F, Denis C, Gonthier R et al (2002) Serum pentosidine as an indicator of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 4(2):93\u201396","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"14","key":"5051_CR68","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1212\/WNL.0b013e3182315a56","volume":"77","author":"K Yaffe","year":"2011","unstructured":"Yaffe K, Lindquist K, Schwartz AV, Vitartas C, Vittinghoff E, Satterfield S et al (2011) Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 77(14):1351\u20131356","journal-title":"Neurology"},{"key":"5051_CR69","doi-asserted-by":"crossref","unstructured":"Haddad M, Perrotte M, Landri S, Lepage A, F\u00fcl\u00f6p T, Ramassamy C (2019 Jun 4) Circulating and extracellular vesicles levels of N-(1-carboxymethyl)-L-lysine (CML) differentiate early to moderate Alzheimer\u2019s disease. In: Krantic S (ed) J Alzheimer\u2019s Dis 69(3):751\u201362","DOI":"10.3233\/JAD-181272"},{"key":"5051_CR70","doi-asserted-by":"publisher","unstructured":"Monacelli F, Borghi R, Pacini D, Serrati C, Traverso N, Odetti P (2014 Jan 1) Pentosidine determination in CSF: a potential biomarker of Alzheimer\u2019s disease? Clin Chem Lab Med [Internet]. [cited 2025 Apr 25];52(1).\u00a0\u00a0https:\/\/doi.org\/10.1515\/cclm-2012-0829\/html","DOI":"10.1515\/cclm-2012-0829\/html"},{"issue":"1","key":"5051_CR71","doi-asserted-by":"publisher","first-page":"e2033012","DOI":"10.1001\/jamanetworkopen.2020.33012","volume":"4","author":"J Chen","year":"2021","unstructured":"Chen J, Mooldijk SS, Licher S, Waqas K, Ikram MK, Uitterlinden AG et al (2021) Assessment of advanced glycation end products and receptors and the risk of dementia. JAMA Netw Open 4(1):e2033012","journal-title":"JAMA Netw Open"},{"key":"5051_CR72","doi-asserted-by":"publisher","unstructured":"Ahmad W, Ijaz B, Shabbiri K, Ahmed F, Rehman S (2017) Oxidative toxicity in diabetes and Alzheimer\u2019s disease: mechanisms behind ROS\/ RNS generation. J Biomed Sci 24(76). https:\/\/doi.org\/10.1186\/s12929-017-0379-z","DOI":"10.1186\/s12929-017-0379-z"},{"issue":"1","key":"5051_CR73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.sjbs.2014.05.003","volume":"22","author":"G Mushtaq","year":"2015","unstructured":"Mushtaq G, Khan JA, Kumosani TA, Kamal MA (2015) Alzheimer\u2019s disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci 22(1):4\u201313","journal-title":"Saudi J Biol Sci"},{"key":"5051_CR74","doi-asserted-by":"crossref","unstructured":"Alam F, Asiful Islam Md, Haryo Sasongko T, Hua Gan S (2016 Sep 1) Type 2 diabetes mellitus and Alzheimer\u2019s disease: bridging the pathophysiology and management. Curr Pharm Des 22(28):4430\u201342","DOI":"10.2174\/1381612822666160527160236"},{"issue":"12","key":"5051_CR75","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.2337\/dc13-0143","volume":"36","author":"C Moran","year":"2013","unstructured":"Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A et al (2013) Brain atrophy in type 2 diabetes. Diabetes Care 36(12):4036\u20134042","journal-title":"Diabetes Care"},{"issue":"24","key":"5051_CR76","doi-asserted-by":"publisher","first-page":"15596","DOI":"10.1073\/pnas.242407999","volume":"99","author":"H Vlassara","year":"2002","unstructured":"Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V et al (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci 99(24):15596\u201315601","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"5051_CR77","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/nu2121247","volume":"2","author":"C Luevano-Contreras","year":"2010","unstructured":"Luevano-Contreras C, Chapman-Novakofski K (2010) Dietary advanced glycation end products and aging. Nutrients 2(12):1247\u20131265","journal-title":"Nutrients"},{"issue":"2","key":"5051_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12551-024-01188-4","volume":"16","author":"AB Uceda","year":"2024","unstructured":"Uceda AB, Mari\u00f1o L, Casasnovas R, Adrover M (2024) An overview on glycation: molecular mechanisms, impact on proteins, pathogenesis, and inhibition. Biophys Rev 16(2):189\u2013218","journal-title":"Biophys Rev"},{"issue":"3","key":"5051_CR79","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41589-024-01644-y","volume":"21","author":"MS Martin","year":"2025","unstructured":"Martin MS, Jacob-Dolan JW, Pham VTT, Sjoblom NM, Scheck RA (2025) The chemical language of protein glycation. Nat Chem Biol 21(3):324\u2013336","journal-title":"Nat Chem Biol"},{"issue":"1","key":"5051_CR80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jfda.2016.10.017","volume":"25","author":"WJ Yeh","year":"2017","unstructured":"Yeh WJ, Hsia SM, Lee WH, Wu CH (2017) Polyphenols with antiglycation activity and mechanisms of action: a review of recent findings. J Food Drug Anal 25(1):84\u201392","journal-title":"J Food Drug Anal"},{"issue":"13","key":"5051_CR81","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/cells12131684","volume":"12","author":"M Portero-Otin","year":"2023","unstructured":"Portero-Otin M, de la Maza MP, Uribarri J (2023) Dietary advanced glycation end products: their role in the insulin resistance of aging. Cells 12(13):1684","journal-title":"Cells"},{"issue":"6","key":"5051_CR82","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ddr.21971","volume":"83","author":"H Singh","year":"2022","unstructured":"Singh H, Agrawal DK (2022) Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug Dev Res 83(6):1257\u20131269","journal-title":"Drug Dev Res"},{"issue":"2","key":"5051_CR83","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1074\/jbc.M110.144097","volume":"286","author":"O Brouwers","year":"2011","unstructured":"Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T et al (2011) Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 286(2):1374\u20131380","journal-title":"J Biol Chem"},{"issue":"4","key":"5051_CR84","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al (2012) Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316\u20131338","journal-title":"J Clin Invest"},{"issue":"1","key":"5051_CR85","doi-asserted-by":"publisher","first-page":"9766","DOI":"10.1038\/s41598-017-09577-4","volume":"7","author":"SM Laws","year":"2017","unstructured":"Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE et al (2017) Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci Rep 7(1):9766","journal-title":"Sci Rep"},{"issue":"6","key":"5051_CR86","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2337\/dc16-2001","volume":"40","author":"LL Ekblad","year":"2017","unstructured":"Ekblad LL, Rinne JO, Puukka P, Laine H, Ahtiluoto S, Sulkava R et al (2017) Insulin resistance predicts cognitive decline: an 11-year follow-up of a nationally representative adult population sample. Diabetes Care 40(6):751\u2013758","journal-title":"Diabetes Care"},{"issue":"12","key":"5051_CR87","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fnins.2018.00215","volume":"10","author":"C Benedict","year":"2018","unstructured":"Benedict C, Grillo CA (2018) Insulin resistance as a therapeutic target in the treatment of Alzheimer\u2019s disease: a state-of-the-art review. Front Neurosci 10(12):215","journal-title":"Front Neurosci"},{"issue":"4","key":"5051_CR88","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Z Cai","year":"2018","unstructured":"Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q (2018) Role of blood-brain barrier in Alzheimer\u2019s disease. J Alzheimers Dis 63(4):1223\u20131234","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"5051_CR89","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jada.2004.05.214","volume":"104","author":"T Goldberg","year":"2004","unstructured":"Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J et al (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104(8):1287\u20131291","journal-title":"J Am Diet Assoc"},{"issue":"3","key":"5051_CR90","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/01.ASN.0000051593.41395.B9","volume":"14","author":"J Uribarri","year":"2003","unstructured":"Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C et al (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14(3):728\u2013731","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"5051_CR91","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.mehy.2009.06.044","volume":"73","author":"A Gugliucci","year":"2009","unstructured":"Gugliucci A (2009) \u201cBlinding\u201d of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? Med Hypotheses 73(6):921\u2013924","journal-title":"Med Hypotheses"},{"issue":"20","key":"5051_CR92","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1001\/jama.288.20.2579","volume":"288","author":"MJ Sheetz","year":"2002","unstructured":"Sheetz MJ (2002) Molecular understanding of hyperglycemia\u2019s adverse effects for diabetic complications. JAMA 288(20):2579","journal-title":"JAMA"},{"issue":"6","key":"5051_CR93","doi-asserted-by":"publisher","first-page":"597","DOI":"10.33549\/physiolres.930234","volume":"51","author":"M Kalousov\u00e1","year":"2002","unstructured":"Kalousov\u00e1 M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51(6):597\u2013604","journal-title":"Physiol Res"},{"issue":"4","key":"5051_CR94","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta G (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63(4):582\u2013592","journal-title":"Cardiovasc Res"},{"issue":"1","key":"5051_CR95","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1433.059","volume":"1126","author":"IK Lukic","year":"2008","unstructured":"Lukic IK, Humpert PM, Nawroth PP, Bierhaus A (2008) The RAGE pathway. Ann N Y Acad Sci 1126(1):76\u201380","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"5051_CR96","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cmet.2018.08.014","volume":"28","author":"J Chaudhuri","year":"2018","unstructured":"Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N et al (2018) The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality. Cell Metab 28(3):337\u2013352","journal-title":"Cell Metab"},{"issue":"4","key":"5051_CR97","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/YCO.0000000000000065","volume":"27","author":"D Giacco","year":"2014","unstructured":"Giacco D, Matanov A, Priebe S (2014) Providing mental healthcare to immigrants. Curr Opin Psychiatry 27(4):282\u2013288","journal-title":"Curr Opin Psychiatry"},{"issue":"6347","key":"5051_CR98","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.aag1095","volume":"357","author":"G Richarme","year":"2017","unstructured":"Richarme G, Liu C, Mihoub M, Abdallah J, Leger T, Joly N et al (2017) Guanine glycation repair by DJ-1\/Park7 and its bacterial homologs. Science 357(6347):208\u2013211","journal-title":"Science"},{"issue":"4","key":"5051_CR99","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4103\/2230-8210.183480","volume":"20","author":"A Chawla","year":"2016","unstructured":"Chawla A, Chawla R, Jaggi S (2016) Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab 20(4):546\u2013551","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"5051_CR100","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/ijms25126429","volume":"25","author":"N Hajd\u00fa","year":"2024","unstructured":"Hajd\u00fa N, R\u00e1cz R, Tordai DZ, B\u00e9keffy M, V\u00e1gi OE, Istenes I et al (2024) Genetic variants influence the development of diabetic neuropathy. Int J Mol Sci 25(12):6429","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5051_CR101","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","volume":"51","author":"LP Dolgacheva","year":"2019","unstructured":"Dolgacheva LP, Berezhnov AV, Fedotova EI, Zinchenko VP, Abramov AY (2019) Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease. J Bioenerg Biomembr 51(3):175\u2013188","journal-title":"J Bioenerg Biomembr"},{"issue":"234","key":"5051_CR102","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","volume":"5","author":"TM Penning","year":"2015","unstructured":"Penning TM (2015) The aldo-keto reductases (AKRs): overview. Chem Biol Interact 5(234):236\u2013246","journal-title":"Chem Biol Interact"},{"issue":"4","key":"5051_CR103","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/2047487319869400","volume":"27","author":"K Lechner","year":"2020","unstructured":"Lechner K, von Schacky C, McKenzie AL, Worm N, Nixdorff U, Lechner B et al (2020) Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors. Eur J Prev Cardiol 27(4):394\u2013406","journal-title":"Eur J Prev Cardiol"},{"issue":"23","key":"5051_CR104","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1523\/JNEUROSCI.21-23-09291.2001","volume":"21","author":"JQ Zheng","year":"2001","unstructured":"Zheng JQ, Kelly TK, Chang B, Ryazantsev S, Rajasekaran AK, Martin KC et al (2001) A functional role for intra-axonal protein synthesis during axonal regeneration from adult sensory neurons. J Neurosci 21(23):9291\u20139303","journal-title":"J Neurosci"},{"issue":"12","key":"5051_CR105","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1016\/j.bbadis.2018.08.036","volume":"1864","author":"S Rowan","year":"2018","unstructured":"Rowan S, Bejarano E, Taylor A (2018) Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochim Biophys Acta Mol Basis Dis 1864(12):3631\u20133643","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"5051_CR106","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.2337\/db14-0375","volume":"63","author":"M Vandal","year":"2014","unstructured":"Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V et al (2014) Insulin reverses the high-fat diet\u2013induced increase in brain A\u03b2 and improves memory in an animal model of Alzheimer disease. Diabetes 63(12):4291\u20134301","journal-title":"Diabetes"},{"issue":"4","key":"5051_CR107","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.neurobiolaging.2005.04.017","volume":"27","author":"CG Glabe","year":"2006","unstructured":"Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27(4):570\u2013575","journal-title":"Neurobiol Aging"},{"issue":"1","key":"5051_CR108","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1038\/s41598-020-60682-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z, Jiao R, Wang P, Zhu Y, Zhao J, De Jager P et al (2020) Shared causal paths underlying Alzheimer\u2019s dementia and type 2 diabetes. Sci Rep 10(1):4107","journal-title":"Sci Rep"},{"issue":"12","key":"5051_CR109","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.2337\/db06-0485","volume":"55","author":"BJ Clodfelder-Miller","year":"2006","unstructured":"Clodfelder-Miller BJ, Zmijewska AA, Johnson GVW, Jope RS (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55(12):3320\u20133325","journal-title":"Diabetes"},{"issue":"1","key":"5051_CR110","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-2006-10113","volume":"10","author":"SM de la Monte","year":"2006","unstructured":"de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer\u2019s disease. J Alzheimers Dis. 10(1):89\u2013109","journal-title":"J Alzheimers Dis."},{"issue":"3","key":"5051_CR111","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron 63(3):287\u2013303","journal-title":"Neuron"},{"issue":"3","key":"5051_CR112","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12035-015-9132-3","volume":"53","author":"P Grieb","year":"2016","unstructured":"Grieb P (2016) Intracerebroventricular streptozotocin injections as a model of Alzheimer\u2019s disease: in search of a relevant mechanism. Mol Neurobiol 53(3):1741\u20131752","journal-title":"Mol Neurobiol"},{"issue":"5","key":"5051_CR113","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/dmrr.1188","volume":"27","author":"KCB Tan","year":"2011","unstructured":"Tan KCB, Shiu SWM, Wong Y, Tam X (2011) Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 27(5):488\u2013492","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"5051_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1755-5922.2010.00177.x","volume":"30","author":"N Tahara","year":"2012","unstructured":"Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N et al (2012) Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 30(1):42\u201348","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"5051_CR115","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0304-4165(00)00113-6","volume":"1523","author":"AC Boyd","year":"2000","unstructured":"Boyd AC, Abdel-Wahab YHA, McKillop AM, McNulty H, Barnett CR, O\u2019Harte FPM et al (2000) Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle. Biochim Biophys Acta BBA - Gen Subj 1523(1):128\u2013134","journal-title":"Biochim Biophys Acta BBA - Gen Subj"},{"issue":"2","key":"5051_CR116","doi-asserted-by":"publisher","first-page":"492","DOI":"10.2337\/diabetes.52.2.492","volume":"52","author":"SJ Hunter","year":"2003","unstructured":"Hunter SJ, Boyd AC, O\u2019Harte FPM, McKillop AM, Wiggam MI, Mooney MH et al (2003) Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes 52(2):492\u2013498","journal-title":"Diabetes"},{"issue":"5","key":"5051_CR117","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0898-6568(01)00152-8","volume":"13","author":"T Naitoh","year":"2001","unstructured":"Naitoh T, Kitahara M, Tsuruzoe N (2001) Tumor necrosis factor-\u03b1 is induced through phorbol ester- and glycated human albumin-dependent pathway in THP-1 cells. Cell Signal 13(5):331\u2013334","journal-title":"Cell Signal"},{"issue":"48","key":"5051_CR118","doi-asserted-by":"publisher","first-page":"47376","DOI":"10.1074\/jbc.M301088200","volume":"278","author":"C Miele","year":"2003","unstructured":"Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P et al (2003) Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C\u03b1-mediated mechanism. J Biol Chem 278(48):47376\u201347387","journal-title":"J Biol Chem"},{"issue":"s1","key":"5051_CR119","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.3233\/JAD-240069","volume":"101","author":"SM de la Monte","year":"2024","unstructured":"de la Monte SM (2024) Conquering insulin network dysfunctions in Alzheimer\u2019s disease: where are we today? J Alzheimers Dis JAD 101(s1):S317\u2013S343","journal-title":"J Alzheimers Dis JAD"},{"issue":"13","key":"5051_CR120","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.3390\/cells12131728","volume":"12","author":"MA Ansari","year":"2023","unstructured":"Ansari MA, Al-Jarallah A, Babiker FA (2023) Impaired insulin signaling alters mediators of hippocampal synaptic dynamics\/plasticity: a possible mechanism of hyperglycemia-induced cognitive impairment. Cells 12(13):1728","journal-title":"Cells"},{"key":"5051_CR121","doi-asserted-by":"publisher","first-page":"e20230032","DOI":"10.1590\/1980-5764-dn-2023-0032","volume":"18","author":"LJO de Andrade","year":"2024","unstructured":"de Andrade LJO, de Oliveira LM, Bittencourt AMV, de Louren\u00e7o LGC, de Oliveira GCM (2024) Brain insulin resistance and Alzheimer\u2019s disease: a systematic review. Dement Neuropsychol 18:e20230032","journal-title":"Dement Neuropsychol"},{"issue":"6","key":"5051_CR122","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2337\/db14-1507","volume":"64","author":"AA Willette","year":"2015","unstructured":"Willette AA, Modanlo N, Kapogiannis D (2015) Alzheimer\u2019s disease neuroimaging initiative. Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. Diabetes 64(6):1933\u201340","journal-title":"Diabetes"},{"issue":"5","key":"5051_CR123","doi-asserted-by":"publisher","first-page":"fcac243","DOI":"10.1093\/braincomms\/fcac243","volume":"4","author":"R Molina-Fern\u00e1ndez","year":"2022","unstructured":"Molina-Fern\u00e1ndez R, Pic\u00f3n-Pag\u00e8s P, Barranco-Almohalla A, Crepin G, Herrera-Fern\u00e1ndez V, Garc\u00eda-El\u00edas A et al (2022) Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide. Brain Commun. 4(5):fcac243","journal-title":"Brain Commun."},{"issue":"28","key":"5051_CR124","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1523\/JNEUROSCI.1071-09.2009","volume":"29","author":"QL Ma","year":"2009","unstructured":"Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ et al (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci Off J Soc Neurosci 29(28):9078\u20139089","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"7","key":"5051_CR125","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1073\/pnas.0230450100","volume":"100","author":"W Farris","year":"2003","unstructured":"Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP et al (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid \u03b2-protein, and the \u03b2-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci 100(7):4162\u20134167","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5051_CR126","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS et al (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 14(3):168\u2013181","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"5051_CR127","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/db13-1954","volume":"63","author":"FG De Felice","year":"2014","unstructured":"De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63(7):2262\u20132272","journal-title":"Diabetes"},{"issue":"1","key":"5051_CR128","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 69(1):29","journal-title":"Arch Neurol"},{"issue":"4","key":"5051_CR129","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM et al (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J 6(4):246\u2013254","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"5051_CR130","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J et al (2010) Dendritic function of tau mediates amyloid-\u03b2 toxicity in Alzheimer\u2019s disease mouse models. Cell 142(3):387\u2013397","journal-title":"Cell"},{"issue":"46","key":"5051_CR131","doi-asserted-by":"publisher","first-page":"45937","DOI":"10.1074\/jbc.M306268200","volume":"278","author":"R Bhat","year":"2003","unstructured":"Bhat R, Xue Y, Berg S, Hellberg S, Orm\u00f6 M, Nilsson Y et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278(46):45937\u201345945","journal-title":"J Biol Chem"},{"issue":"31","key":"5051_CR132","doi-asserted-by":"publisher","first-page":"19547","DOI":"10.1074\/jbc.272.31.19547","volume":"272","author":"M Hong","year":"1997","unstructured":"Hong M, Lee VMY (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272(31):19547\u201319553","journal-title":"J Biol Chem"},{"issue":"12","key":"5051_CR133","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00018-003-3305-3","volume":"60","author":"SM de la Monte","year":"2003","unstructured":"de la Monte SM, Chen GJ, Rivera E, Wands JR (2003) Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci CMLS 60(12):2679\u20132691","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"8","key":"5051_CR134","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1097\/00001756-200006050-00032","volume":"11","author":"B Hauss-Wegrzyniak","year":"2000","unstructured":"Hauss-Wegrzyniak B, Vraniak PD, Wenk GL (2000) LPS-induced neuroinflammatory effects do not recover with time. NeuroReport 11(8):1759\u20131763","journal-title":"NeuroReport"},{"issue":"1","key":"5051_CR135","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbr.2012.01.010","volume":"229","author":"MS Kahn","year":"2012","unstructured":"Kahn MS, Kranjac D, Alonzo CA, Haase JH, Cedillos RO, McLinden KA et al (2012) Prolonged elevation in hippocampal A\u03b2 and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res 229(1):176\u2013184","journal-title":"Behav Brain Res"},{"issue":"22","key":"5051_CR136","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1212\/WNL.0000000000003391","volume":"87","author":"X Zhan","year":"2016","unstructured":"Zhan X, Stamova B, Jin LW, DeCarli C, Phinney B, Sharp FR (2016) Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology 87(22):2324\u20132332","journal-title":"Neurology"},{"issue":"1\u20132","key":"5051_CR137","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jneuroim.2008.09.017","volume":"206","author":"R Zhang","year":"2009","unstructured":"Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M et al (2009) Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 206(1\u20132):121\u2013124","journal-title":"J Neuroimmunol"},{"issue":"1","key":"5051_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00394-017-1445-8","volume":"57","author":"I Rowland","year":"2018","unstructured":"Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I et al (2018) Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 57(1):1\u201324","journal-title":"Eur J Nutr"},{"issue":"4","key":"5051_CR139","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/nu12041082","volume":"12","author":"R Chakaroun","year":"2020","unstructured":"Chakaroun R, Massier L, Kovacs P (2020) Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? Nutrients 12(4):1082","journal-title":"Nutrients"},{"issue":"6265","key":"5051_CR140","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aac8469","volume":"350","author":"PW O\u2019Toole","year":"2015","unstructured":"O\u2019Toole PW, Jeffery IB (2015) Gut microbiota and aging. Science 350(6265):1214\u20131215","journal-title":"Science"},{"issue":"1","key":"5051_CR141","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10522-015-9578-8","volume":"17","author":"D Frasca","year":"2016","unstructured":"Frasca D, Blomberg BB (2016) Inflammaging decreases adaptive and innate immune responses in mice and humans. Biogerontology 17(1):7\u201319","journal-title":"Biogerontology"},{"issue":"40","key":"5051_CR142","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.2174\/1381612822666160907093807","volume":"22","author":"C K\u00f6hler","year":"2016","unstructured":"K\u00f6hler C, Maes M, Slyepchenko A, Berk M, Solmi M, Lanct\u00f4t K et al (2016) The gut-brain axis, including the microbiome, leaky gut and bacterial translocation: mechanisms and pathophysiological role in Alzheimer\u2019s disease. Curr Pharm Des 22(40):6152\u20136166","journal-title":"Curr Pharm Des"},{"issue":"1","key":"5051_CR143","doi-asserted-by":"publisher","first-page":"e002091","DOI":"10.1136\/bmjdrc-2020-002091","volume":"9","author":"C Guillon","year":"2021","unstructured":"Guillon C, Ferraro S, Cl\u00e9ment S, Bouschbacher M, Sigaudo-Roussel D, Bonod C (2021) Glycation by glyoxal leads to profound changes in the behavior of dermal fibroblasts. BMJ Open Diabetes Res Care 9(1):e002091","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"5051_CR144","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2020.06.011","volume":"32","author":"H Wu","year":"2020","unstructured":"Wu H, Tremaroli V, Schmidt C, Lundqvist A, Olsson LM, Kr\u00e4mer M et al (2020) The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metab 32(3):379-390.e3","journal-title":"Cell Metab"},{"issue":"9","key":"5051_CR145","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1039\/C9FO01062A","volume":"10","author":"F Yan","year":"2019","unstructured":"Yan F, Li N, Shi J, Li H, Yue Y, Jiao W et al (2019) Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice. Food Funct 10(9):5804\u20135815","journal-title":"Food Funct"},{"issue":"9","key":"5051_CR146","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Van Giau V (2020) Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci 21(9):3165","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5051_CR147","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/biomedicines10040778","volume":"10","author":"A Athanasaki","year":"2022","unstructured":"Athanasaki A, Melanis K, Tsantzali I, Stefanou MI, Ntymenou S, Paraskevas SG et al (2022) Type 2 diabetes mellitus as a risk factor for Alzheimer\u2019s disease: review and meta-analysis. Biomedicines 10(4):778","journal-title":"Biomedicines"},{"issue":"2","key":"5051_CR148","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.sjbs.2019.12.028","volume":"27","author":"RL Jayaraj","year":"2020","unstructured":"Jayaraj RL, Azimullah S, Beiram R (2020) Diabetes as a risk factor for Alzheimer\u2019s disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci 27(2):736\u2013750","journal-title":"Saudi J Biol Sci"},{"key":"5051_CR149","doi-asserted-by":"publisher","unstructured":"Antal B, McMahon LP, Sultan SF, Lithen A, Wexler DJ, Dickerson B,\u00a0Ratai EM,\u00a0Mujica-Parodi LR (2022) Type 2 diabetes mellitus accelerates brain aging and cognitive decline: complementary findings from UK Biobank and meta-analyses. eLife\u00a011:e73138. https:\/\/doi.org\/10.7554\/eLife.73138","DOI":"10.7554\/eLife.73138"},{"issue":"3","key":"5051_CR150","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2213-8587(13)70192-X","volume":"2","author":"RH Tuligenga","year":"2014","unstructured":"Tuligenga RH, Dugravot A, Tab\u00e1k AG, Elbaz A, Brunner EJ, Kivim\u00e4ki M et al (2014) Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol 2(3):228\u2013235","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"5051_CR151","first-page":"2702","volume":"21","author":"Y Chen","year":"2017","unstructured":"Chen Y, Wang J, Wang LJ, Lin H, Huang PJ (2017) Effect of different blood glucose intervention plans on elderly people with type 2 diabetes mellitus combined with dementia. Eur Rev Med Pharmacol Sci 21(11):2702\u20132707","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5051_CR152","doi-asserted-by":"publisher","unstructured":"Chester B, Babu JR, Greene MW, Geetha T (2019) The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 35(8):e3188. https:\/\/doi.org\/10.1002\/dmrr.3188","DOI":"10.1002\/dmrr.3188"},{"issue":"9","key":"5051_CR153","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jalz.2014.11.009","volume":"11","author":"MC Morris","year":"2015","unstructured":"Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT (2015) MIND diet associated with reduced incidence of Alzheimer\u2019s disease. Alzheimers Dement 11(9):1007\u20131014","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5051_CR154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.plefa.2003.09.007","volume":"70","author":"RL Veech","year":"2004","unstructured":"Veech RL (2004) The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 70(3):309\u2013319","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"5051_CR155","doi-asserted-by":"publisher","unstructured":"Batch JT, Lamsal SP, Adkins M, Sultan S, Ramirez MN (2020) Advantages and disadvantages of the ketogenic diet: a review article. Cureus 12(8):e9639. https:\/\/doi.org\/10.7759\/cureus.9639","DOI":"10.7759\/cureus.9639"},{"issue":"1","key":"5051_CR156","doi-asserted-by":"publisher","first-page":"15265","DOI":"10.1038\/s41598-021-94048-0","volume":"11","author":"Y Chung","year":"2021","unstructured":"Chung Y, Lee H, Weiner MW, Aisen P, Petersen R, Jack CR et al (2021) Correlation between Alzheimer\u2019s disease and type 2 diabetes using non-negative matrix factorization. Sci Rep 11(1):15265","journal-title":"Sci Rep"},{"issue":"1","key":"5051_CR157","doi-asserted-by":"publisher","first-page":"e12202","DOI":"10.1016\/j.heliyon.2022.e12202","volume":"9","author":"M Afzal","year":"2023","unstructured":"Afzal M, Alharbi KS, Alzarea SI, Alyamani NM, Kazmi I, G\u00fcven E (2023) Revealing genetic links of type 2 diabetes that lead to the development of Alzheimer\u2019s disease. Heliyon 9(1):e12202","journal-title":"Heliyon"},{"key":"5051_CR158","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jns.2017.07.044","volume":"380","author":"XF Wang","year":"2017","unstructured":"Wang XF, Lin X, Li DY, Zhou R, Greenbaum J, Chen YC et al (2017) Linking Alzheimer\u2019s disease and type 2 diabetes: novel shared susceptibility genes detected by cFDR approach. J Neurol Sci 380:262\u2013272","journal-title":"J Neurol Sci"},{"key":"5051_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/7420796","volume":"2017","author":"GD Femminella","year":"2017","unstructured":"Femminella GD, Bencivenga L, Petraglia L, Visaggi L, Gioia L, Grieco FV et al (2017) Antidiabetic drugs in Alzheimer\u2019s disease: mechanisms of action and future perspectives. J Diabetes Res 2017:1\u20137","journal-title":"J Diabetes Res"},{"issue":"15","key":"5051_CR160","doi-asserted-by":"publisher","first-page":"12486","DOI":"10.3390\/ijms241512486","volume":"24","author":"G Plascencia-Villa","year":"2023","unstructured":"Plascencia-Villa G, Perry G (2023) Exploring molecular targets for mitochondrial therapies in neurodegenerative diseases. Int J Mol Sci 24(15):12486","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5051_CR161","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.3390\/ijms23094641","volume":"23","author":"M Michailidis","year":"2022","unstructured":"Michailidis M, Tata DA, Moraitou D, Kavvadas D, Karachrysafi S, Papamitsou T et al (2022) Antidiabetic drugs in the treatment of Alzheimer\u2019s disease. Int J Mol Sci 23(9):4641","journal-title":"Int J Mol Sci"},{"key":"5051_CR162","doi-asserted-by":"publisher","first-page":"4847812","DOI":"10.1155\/2016\/4847812","volume":"2016","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Tang Y, Jin X, Chen C, Lu Y, Liu L et al (2016) Metformin inhibits advanced glycation end products-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE\/NF\u03baB pathway suppression. J Diabetes Res 2016:4847812","journal-title":"J Diabetes Res"},{"issue":"7","key":"5051_CR163","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jgs.18306","volume":"71","author":"H Tang","year":"2023","unstructured":"Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S et al (2023) Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc 71(7):2096\u20132106","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"5051_CR164","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","volume":"47","author":"A Dei Cas","year":"2024","unstructured":"Dei Cas A, Micheli MM, Aldigeri R, Gardini S, Ferrari-Pellegrini F, Perini M et al (2024) Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. J Endocrinol Invest 47(9):2339\u20132349","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"5051_CR165","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","volume":"35","author":"M Hallschmid","year":"2021","unstructured":"Hallschmid M (2021) Intranasal insulin for Alzheimer\u2019s disease. CNS Drugs 35(1):21\u201337","journal-title":"CNS Drugs"},{"issue":"3","key":"5051_CR166","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbrc.2009.12.075","volume":"391","author":"Y Ishibashi","year":"2010","unstructured":"Ishibashi Y, Matsui T, Takeuchi M, Yamagishi SI (2010) Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 391(3):1405\u20138","journal-title":"Biochem Biophys Res Commun"},{"key":"5051_CR167","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","volume":"28","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, Kang EH (2024) Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study. BMJ 28:e079475","journal-title":"BMJ"},{"issue":"16","key":"5051_CR168","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/nu15163585","volume":"15","author":"VA Ruiz-Pozo","year":"2023","unstructured":"Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, Frias-Toral E, Guevara-Ram\u00edrez P, Paz-Cruz E et al (2023) The molecular mechanisms of the relationship between insulin resistance and Parkinson\u2019s disease pathogenesis. Nutrients 15(16):3585","journal-title":"Nutrients"},{"issue":"4","key":"5051_CR169","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3233\/JAD-161256","volume":"57","author":"S Craft","year":"2017","unstructured":"Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH et al (2017) Effects of regular and long-acting insulin on cognition and Alzheimer\u2019s disease biomarkers: a pilot clinical trial. J Alzheimers Dis 57(4):1325\u20131334","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"5051_CR170","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1517\/17425247.2013.856877","volume":"10","author":"SM de la Monte","year":"2013","unstructured":"de la Monte SM (2013) Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv 10(12):1699\u20131709","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"5051_CR171","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","volume":"35","author":"JJ Lochhead","year":"2015","unstructured":"Lochhead JJ, Wolak DJ, Pizzo ME, Thorne RG (2015) Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab 35(3):371\u2013381","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"5051_CR172","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA et al (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-\u03b2 in memory-impaired older adults. J Alzheimers Dis 13(3):323\u2013331","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5051_CR173","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"5051_CR174","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","volume":"164","author":"NM Maruthur","year":"2016","unstructured":"Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z et al (2016) Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes. Ann Intern Med 164(11):740","journal-title":"Ann Intern Med"},{"issue":"7","key":"5051_CR175","doi-asserted-by":"publisher","first-page":"916","DOI":"10.4239\/wjd.v12.i7.916","volume":"12","author":"M Infante","year":"2021","unstructured":"Infante M, Leoni M, Caprio M, Fabbri A (2021) Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes 12(7):916\u2013931","journal-title":"World J Diabetes"},{"issue":"3","key":"5051_CR176","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JAD-2011-101524","volume":"24","author":"CC Hsu","year":"2011","unstructured":"Hsu CC, Wahlqvist ML, Lee MS, Tsai HN (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 24(3):485\u2013493","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5051_CR177","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","volume":"31","author":"AM Koenig","year":"2017","unstructured":"Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L et al (2017) Effects of the Insulin Sensitizer Metformin In Alzheimer disease. Alzheimer Dis Assoc Disord 31(2):107\u2013113","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"5051_CR178","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113(3):546\u2013593","journal-title":"Pharmacol Ther"},{"issue":"4","key":"5051_CR179","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1124\/pr.108.000604","volume":"60","author":"W Kim","year":"2008","unstructured":"Kim W, Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60(4):470\u2013512","journal-title":"Pharmacol Rev"},{"issue":"2","key":"5051_CR180","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","volume":"129","author":"S Amor","year":"2010","unstructured":"Amor S, Puentes F, Baker D, Van Der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154\u2013169","journal-title":"Immunology"},{"issue":"1","key":"5051_CR181","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","volume":"14","author":"S Tsalamandris","year":"2019","unstructured":"Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S et al (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol Rev 14(1):50\u201359","journal-title":"Eur Cardiol Rev"},{"issue":"2\u20133","key":"5051_CR182","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12035-010-8106-8","volume":"41","author":"LF Lue","year":"2010","unstructured":"Lue LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer\u2019s disease. Mol Neurobiol 41(2\u20133):115\u2013128","journal-title":"Mol Neurobiol"},{"key":"5051_CR183","first-page":"9","volume":"27","author":"S Xu","year":"2021","unstructured":"Xu S, Zhang X, Liu C, Liu Q, Chai H, Luo Y et al (2021) Role of mitochondria in neurodegenerative diseases: from an epigenetic perspective. Front Cell Dev Biol 27:9","journal-title":"Front Cell Dev Biol"},{"issue":"35","key":"5051_CR184","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.2174\/1381612820666140305224906","volume":"20","author":"M Uittenbogaard","year":"2014","unstructured":"Uittenbogaard M, Chiaramello A (2014) Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des 20(35):5574\u20135593","journal-title":"Curr Pharm Des"},{"issue":"4","key":"5051_CR185","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/ars.2009.2531","volume":"12","author":"WI Sivitz","year":"2010","unstructured":"Sivitz WI, Yorek MA (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12(4):537\u2013577","journal-title":"Antioxid Redox Signal"},{"key":"5051_CR186","doi-asserted-by":"publisher","first-page":"123001","DOI":"10.1016\/j.lfs.2024.123001","volume":"355","author":"J Tran","year":"2024","unstructured":"Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS (2024) Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges. Life Sci 355:123001","journal-title":"Life Sci"},{"issue":"4","key":"5051_CR187","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/1559827617708991","volume":"13","author":"C Prasad","year":"2019","unstructured":"Prasad C, Davis KE, Imrhan V, Juma S, Vijayagopal P (2019) Advanced glycation end products and risks for chronic diseases: intervening through lifestyle modification. Am J Lifestyle Med 13(4):384\u2013404","journal-title":"Am J Lifestyle Med"},{"issue":"19","key":"5051_CR188","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/nu14193982","volume":"14","author":"A Zawada","year":"2022","unstructured":"Zawada A, Machowiak A, Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Dobrowolska A et al (2022) Accumulation of advanced glycation end-products in the body and dietary habits. Nutrients 14(19):3982","journal-title":"Nutrients"},{"issue":"11","key":"5051_CR189","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3390\/antiox10111724","volume":"10","author":"C Pasten","year":"2021","unstructured":"Pasten C, Lozano M, Rocco J, Carri\u00f3n F, Alvarado C, Liberona J et al (2021) Aminoguanidine prevents the oxidative stress, inhibiting elements of inflammation, endothelial activation, mesenchymal markers, and confers a renoprotective effect in renal ischemia and reperfusion injury. Antioxid Basel Switz 10(11):1724","journal-title":"Antioxid Basel Switz"},{"issue":"3","key":"5051_CR190","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JAD-200896","volume":"78","author":"GE Gibson","year":"2020","unstructured":"Gibson GE, Luchsinger JA, Cirio R, Chen H, Franchino-Elder J, Hirsch JA et al (2020) Benfotiamine and cognitive decline in Alzheimer\u2019s disease: results of a randomized placebo-controlled phase IIa clinical trial. J Alzheimers Dis 78(3):989\u20131010","journal-title":"J Alzheimers Dis"},{"key":"5051_CR191","doi-asserted-by":"crossref","unstructured":"Feldman HH, Luchsinger JA, L\u00e9ger GC, Taylor C, Jacobs DM, Salmon DP et al (2024 May 29) Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer\u2019s disease (BenfoTeam). In: Campbell E (ed) PLOS ONE 19(5):e0302998","DOI":"10.1371\/journal.pone.0302998"},{"key":"5051_CR192","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/DDDT.S296197","volume":"15","author":"L Sheng","year":"2021","unstructured":"Sheng L, Cao W, Lin P, Chen W, Xu H, Zhong C et al (2021) Safety, tolerability and pharmacokinetics of single and multiple ascending doses of benfotiamine in healthy subjects. Drug Des Devel Ther 15:1101\u20131110","journal-title":"Drug Des Devel Ther"},{"key":"5051_CR193","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejmech.2018.11.049","volume":"163","author":"P Srivastava","year":"2019","unstructured":"Srivastava P, Tripathi PN, Sharma P, Rai SN, Singh SP, Srivastava RK et al (2019) Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur J Med Chem 163:116\u2013135","journal-title":"Eur J Med Chem"},{"issue":"2","key":"5051_CR194","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JAD-150493","volume":"51","author":"JA Luchsinger","year":"2016","unstructured":"Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G et al (2016) Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis JAD 51(2):501\u2013514","journal-title":"J Alzheimers Dis JAD"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05051-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05051-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05051-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:03:20Z","timestamp":1759997000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05051-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":194,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5051"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05051-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}